Switch theme
Sign up to access all valuation multiples
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
1986
8.8K+
LTM Revenue $3.8B
LTM EBITDA $788M
$7.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aurobindo Pharma has a last 12-month revenue (LTM) of $3.8B and a last 12-month EBITDA of $788M.
In the most recent fiscal year, Aurobindo Pharma achieved revenue of $3.7B and an EBITDA of $840M.
Aurobindo Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aurobindo Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.8B | XXX | $3.7B | XXX | XXX | XXX |
| Gross Profit | $2.2B | XXX | $2.1B | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $788M | XXX | $840M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $590M | XXX | $580M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $420M | XXX | $408M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $278M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Aurobindo Pharma's stock price is INR 1148 (or $13).
Aurobindo Pharma has current market cap of INR 667B (or $7.8B), and EV of INR 664B (or $7.8B).
See Aurobindo Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.8B | $7.8B | XXX | XXX | XXX | XXX | $0.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Aurobindo Pharma has market cap of $7.8B and EV of $7.8B.
Aurobindo Pharma's trades at 2.2x EV/Revenue multiple, and 9.6x EV/EBITDA.
Equity research analysts estimate Aurobindo Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aurobindo Pharma has a P/E ratio of 18.6x.
See valuation multiples for Aurobindo Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.8B | XXX | $7.8B | XXX | XXX | XXX |
| EV (current) | $7.8B | XXX | $7.8B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 9.9x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBIT | 13.2x | XXX | 13.8x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.6x | XXX | 19.6x | XXX | XXX | XXX |
| EV/FCF | 40.2x | XXX | 86.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAurobindo Pharma's last 12 month revenue growth is 8%
Aurobindo Pharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Aurobindo Pharma's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aurobindo Pharma's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Aurobindo Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 5% | XXX | XXX | XXX |
| Rule of 40 | 30% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aurobindo Pharma acquired XXX companies to date.
Last acquisition by Aurobindo Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Aurobindo Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Aurobindo Pharma founded? | Aurobindo Pharma was founded in 1986. |
| Where is Aurobindo Pharma headquartered? | Aurobindo Pharma is headquartered in India. |
| How many employees does Aurobindo Pharma have? | As of today, Aurobindo Pharma has 8.8K+ employees. |
| Is Aurobindo Pharma publicy listed? | Yes, Aurobindo Pharma is a public company listed on NSE. |
| What is the stock symbol of Aurobindo Pharma? | Aurobindo Pharma trades under AUROPHARMA ticker. |
| When did Aurobindo Pharma go public? | Aurobindo Pharma went public in 2000. |
| Who are competitors of Aurobindo Pharma? | Similar companies to Aurobindo Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Aurobindo Pharma? | Aurobindo Pharma's current market cap is $7.8B |
| What is the current revenue of Aurobindo Pharma? | Aurobindo Pharma's last 12 months revenue is $3.8B. |
| What is the current revenue growth of Aurobindo Pharma? | Aurobindo Pharma revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Aurobindo Pharma? | Current revenue multiple of Aurobindo Pharma is 2.1x. |
| Is Aurobindo Pharma profitable? | Yes, Aurobindo Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Aurobindo Pharma? | Aurobindo Pharma's last 12 months EBITDA is $788M. |
| What is Aurobindo Pharma's EBITDA margin? | Aurobindo Pharma's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Aurobindo Pharma? | Current EBITDA multiple of Aurobindo Pharma is 9.9x. |
| What is the current FCF of Aurobindo Pharma? | Aurobindo Pharma's last 12 months FCF is $193M. |
| What is Aurobindo Pharma's FCF margin? | Aurobindo Pharma's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Aurobindo Pharma? | Current FCF multiple of Aurobindo Pharma is 40.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
